Q2 2026 revenue grew 18% year-over-year to $10.9M, driven by strong neurosurgery navigation and IRRAflow sales, while Biologics and Drug Delivery declined due to a non-recurring order. Strategic focus shifted to clinical support, CAL facility expansion, and technology development, with 2026 revenue guidance set at $48–$52M and high-teen to 20% growth expected in 2027.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.